CLINICAL_TRIALS
trial_result
· 2017-02-01
Clinical Trial Update: Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV [Phase 3]
Summary
Phase 3 study of clevudine 30 mg once daily in HBeAg-negative chronic hepatitis B was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bukwang Pharmaceutical | Conditions: Hepatitis B | Phase 3 | Status: TERMINATED